J Neurosurg. 2018 Apr;128(4):999-1005. doi: 10.3171/2017.1.JNS16745. Epub 2017 Jul 7.
OBJECTIVE Despite a hemorrhagic presentation, many patients with arteriovenous malformations (AVMs) do not require emergency resection. The timing of definitive management is not standardized in the cerebrovascular community. This study was designed to evaluate the safety of delaying AVM treatment in clinically stable patients with a new hemorrhagic presentation. The authors examined the rate of rehemorrhage or neurological decline in a cohort of patients with ruptured brain AVMs during a period of time posthemorrhage. METHODS Patients presenting to the authors' institution from January 2000 to December 2015 with ruptured brain AVMs treated at least 4 weeks posthemorrhage were included in this analysis. Exclusion criteria were ruptured AVMs that required emergency surgery involving resection of the AVM, prior treatment of AVM at another institution, or treatment of lesions within 4 weeks for other reasons (subacute surgery). The primary outcome measure was time from initial hemorrhage to treatment failure (defined as rehemorrhage or neurological decline as a direct result of the AVM). Patient-days were calculated from the day of initial rupture until the day AVM treatment was initiated or treatment failed. RESULTS Of 102 ruptured AVMs in 102 patients meeting inclusion criteria, 7 (6.9%) failed the treatment paradigm. Six patients (5.8%) had a new hemorrhage within a median of 248 days (interquartile range 33-1364 days). The total "at risk" period was 18,740 patient-days, yielding a rehemorrhage rate of 11.5% per patient-year, or 0.96% per patient-month. Twelve (11.8%) of 102 patients were found to have an associated aneurysm. In this group there was a single (8.3%) new hemorrhage during a total at-risk period of 263 patient-days until the aneurysm was secured, yielding a rehemorrhage risk of 11.4% per patient-month. CONCLUSIONS It is the authors' practice to rehabilitate patients after brain AVM rupture with a plan for elective treatment of the AVM. The present data are useful in that the findings quantify the risk of the authors' treatment strategy. These findings indicate that delaying intervention for at least 4 weeks after the initial hemorrhage subjects the patient to a low (< 1%) risk of rehemorrhage. The authors modified the treatment paradigm when a high-risk feature, such as an associated intracranial aneurysm, was identified.
尽管表现为出血,但许多动静脉畸形(AVM)患者并不需要紧急切除。脑血管病领域尚未对明确治疗的时机进行标准化。本研究旨在评估在有新出血表现的临床稳定患者中延迟 AVM 治疗的安全性。作者在出血后一段时间内,检查了一组破裂脑 AVM 患者的再出血或神经功能下降的发生率。
本分析纳入了 2000 年 1 月至 2015 年 12 月期间在作者所在机构就诊的、经至少 4 周治疗后破裂脑 AVM 患者。排除标准为需要切除 AVM 的紧急手术、在其他机构进行过 AVM 治疗或在 4 周内因其他原因(亚急性手术)进行治疗的破裂 AVM。主要结局指标为从初次出血到治疗失败的时间(定义为 AVM 直接导致的再出血或神经功能下降)。从初次破裂的当天到开始 AVM 治疗或治疗失败的当天计算患者的天数。
在符合纳入标准的 102 例破裂 AVM 患者中,有 7 例(6.9%)治疗失败。6 例(5.8%)患者在中位时间 248 天(四分位间距 33-1364 天)内发生新出血。总“风险”期为 18740 患者天,导致患者年再出血率为 11.5%,患者月再出血率为 0.96%。102 例患者中有 12 例(11.8%)发现有相关动脉瘤。在这组患者中,在动脉瘤得到固定之前,总共 263 患者天的“风险”期内发生了单次(8.3%)新出血,导致患者月再出血风险为 11.4%。
作者的做法是在脑 AVM 破裂后对患者进行康复治疗,并制定 AVM 的择期治疗计划。本研究的数据有助于量化作者治疗策略的风险。这些发现表明,在初次出血后至少 4 周延迟干预会使患者再出血的风险低于 1%(低风险)。当存在高风险特征(如颅内动脉瘤)时,作者会修改治疗方案。